Breast Cancer Clinical Trial
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Summary
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.
Full Description
TAS2940 is a small molecule inhibitor of ERBB family proteins HER2 and EGFR. It has not been evaluated in human subjects yet. The study will be conducted in 2 parts, dose escalation and dose expansion. The dose escalation part will assess the safety and determine the maximum tolerated dose, the recommended phase 2 dose and the recommended dosing regimen of TAS2940 administered orally. The dose expansion part will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations.
Eligibility Criteria
Inclusion Criteria:
Have histologically confirmed solid cancer that is locally advanced and metastatic and available standard treatment options have been exhausted
Have adequate organ function
ECOG PS 0-1
Dose Escalation:
Have measurable or non- measurable disease per RECIST criteria v1.1 or RANO
Any solid tumor with EGFR and / or HER2 aberration
Dose Expansion:
Have measurable disease per RECIST criteria v1.1 for solid tumor (excluding primary brain tumor) or RANO (for glioblastoma)
Cohort A: Non-small cell lung cancer (NSCLC)
Cohort B: HER2 positive breast cancer
Cohort C: Recurrent or refractory glioblastoma
Cohort D: Other solid tumors with EGFR or HER2 aberrations
Exclusion Criteria:
Non-stable brain metastases
Have significant cardiovascular disorder
Have not recovered from prior cancer treatment
A serious illness or medical condition
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Nashville Tennessee, 37203, United States
Houston Texas, 77030, United States
Villejuif Cedex, 94805, France
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.